Florence-based A. Menarini Diagnostics, part of the Menarini Group and Trieste-based, Ulisse BioMed S.P.A, announced today that they have entered into a Transfer of Technology agreement for a world-class sensitive diagnostic test for SARS-CoV-2. Under the same agreement, A.Menarini Diagnostics and Ulisse BioMed will cooperate for the development of a full Molecular Diagnostics respiratory panel.
Under this agreement, Menarini will become the manufacturer of the SARS-CoV-2 assay, called CoronaMelt, and distribute the product on a Worldwide basis.
The CoronaMelt is a fast, cost efficient and highly sensitive solution to address laboratory needs. It can provide a highly specific SARS-CoV-2 virus testing, tightly discriminating the infection from other respiratory infections, such as common flu. The CoronaMelt allows the detection of the viral genome directly from crude biological samples, without any nucleic acid extraction step, thus saving time and reagents.
CoronaMelt is an open , variety of PCR machines already present on the market and manual laboratory set-ups
“We are extremely pleased with this new partnership, that is allowing our company to offer to the market a fast and cost-efficient solution to continue the fight against Covid-19 and start developing a complete Respiratory panel”, said Fabio Piazzalunga, General Manager of A. Menarini Diagnostics. “It is a milestone for Menarini, to step in the production of Molecular Diagnostic, something that is the core of our long-term strategy.”
“UBM is very excited about this agreement with the Menarini Group”, said Saverio Scelz, CEO at Ulisse BioMed S.p.A. “This is the result of five years of research that was carried out by the UBM scientific team in Trieste. They successfully developed a platform that can be easily used for many pathogens. In addition, Ulisse BioMed is developing other patented researches and considers this agreement a major milestone for future important deals. I would like to thank the Copernico SIM team for their support”.